1
Clinical Trials associated with GSK-2231395AAn Observer-blind, Safety Study of GSK Biologicals' Haemophilus Influenzae and Streptococcus Pneumoniae Candidate Vaccine in Adults.
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK2231395A candidate vaccine in adults and elderly adults with chronic obstructive pulmonary disease. Subjects will be vaccinated 3 times with an interval of respectively 2 and 10 months.
100 Clinical Results associated with GSK-2231395A
100 Translational Medicine associated with GSK-2231395A
100 Patents (Medical) associated with GSK-2231395A
100 Deals associated with GSK-2231395A